Inhibrx Biosciences (INBX) EBIT (2023 - 2025)
Historic EBIT for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.
- Inhibrx Biosciences' EBIT rose 2774.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 5834.88%. This contributed to the annual value of -$331.4 million for FY2024, which is 5119.35% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' EBIT is -$33.8 million, which was up 2774.75% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' EBIT ranged from a high of -$27.4 million in Q2 2025 and a low of -$160.9 million during Q2 2024
- Over the past 3 years, Inhibrx Biosciences' median EBIT value was -$46.3 million (recorded in 2023), while the average stood at -$61.1 million.
- Per our database at Business Quant, Inhibrx Biosciences' EBIT tumbled by 28921.6% in 2024 and then surged by 8297.74% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' EBIT stood at -$88.3 million in 2023, then surged by 43.45% to -$49.9 million in 2024, then surged by 32.28% to -$33.8 million in 2025.
- Its last three reported values are -$33.8 million in Q3 2025, -$27.4 million for Q2 2025, and -$42.9 million during Q1 2025.